Skip to main content

Advertisement

SpringerLink
Log in

Pharmacologic prevention of venous thromboembolism in obese patients

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Venous thromboembolism, a collective term for pulmonary embolism and deep venous thrombosis accounts for a large amount of mortality and morbidity in hospitalized patients. Obesity has been considered as an important risk factor for the development of venous thromboembolism. Anticoagulation with fixed doses of low molecular weight heparin, anti-factor Xa inhibitors and unfractionated heparin is widely used in hospitals and has shown to be an effective measure in prevention of venous thromboembolism in multiple major randomized, double-blind controlled trials. Appropriate dosing of anticoagulation in obese patients is still controversial, since obese and morbidly obese population of patients is consistently underrepresented or often excluded from most clinical trials, raising a concern for adequacy of standard dosing in this high risk population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM, American College of Chest P (2012) Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e227S–e277S. doi:10.1378/chest.11-2297

    Article  PubMed  CAS  Google Scholar 

  2. Spyropoulos AC, Mahan C (2009) Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med 122(12):1077–1084. doi:10.1016/j.amjmed.2009.04.027

    Article  PubMed  Google Scholar 

  3. Anderson FA, Jr., Wheeler HB (1992) Physician practices in the management of venous thromboembolism: a community-wide survey. Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 16 (5):707–714

    Google Scholar 

  4. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303(3):235–241. doi:10.1001/jama.2009.2014

    Article  PubMed  CAS  Google Scholar 

  5. Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB, Camargo CA (2009) Prospective study of BMI and the risk of pulmonary embolism in women. Obesity 17(11):2040–2046. doi:10.1038/oby.2009.92

    Article  PubMed  Google Scholar 

  6. Blaszyk H, Bjornsson J (2000) Factor V leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg 135(12):1410–1413

    Article  PubMed  CAS  Google Scholar 

  7. Stein PD, Beemath A, Olson RE (2005) Obesity as a risk factor in venous thromboembolism. Am J Med 118(9):978–980. doi:10.1016/j.amjmed.2005.03.012

    Article  PubMed  Google Scholar 

  8. Heit JA (2002) Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost 28(Suppl 2):3–13. doi:10.1055/s-2002-32312

    Article  PubMed  Google Scholar 

  9. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA (2008) Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 168(15):1678–1683. doi:10.1001/archinte.168.15.1678

    Article  PubMed  Google Scholar 

  10. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM, Melton LJ 3rd (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86(1):452–463

    PubMed  CAS  Google Scholar 

  11. Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9–I16. doi:10.1161/01.CIR.0000078469.07362.E6

    PubMed  Google Scholar 

  12. Eriksson S, Backman L, Ljungstrom KG (1997) The incidence of clinical postoperative thrombosis after gastric surgery for obesity during 16 years. Obes surg 7(4):332–335. doi:10.1381/096089297765555575 Discussion 336

    Article  PubMed  CAS  Google Scholar 

  13. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR (1981) Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26(2):115–117

    PubMed  CAS  Google Scholar 

  14. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med 341(11):793–800. doi:10.1056/NEJM199909093411103

    Article  PubMed  CAS  Google Scholar 

  15. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, Group PMTS (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110(7):874–879. doi:10.1161/01.CIR.0000138928.83266.24

    Article  Google Scholar 

  16. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, Investigators A (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332(7537):325–329. doi:10.1136/bmj.38733.466748.7C

    Article  PubMed  CAS  Google Scholar 

  17. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, American College of Chest P (2012) Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S. doi:10.1378/chest.11-2301

    Article  PubMed  CAS  Google Scholar 

  18. Christiaens V, Lijnen HR (2010) Angiogenesis and development of adipose tissue. Mol Cell Endocrinol 318(1–2):2–9. doi:10.1016/j.mce.2009.08.006

    Article  PubMed  CAS  Google Scholar 

  19. Matsuzawa Y (2006) Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3(1):35–42. doi:10.1038/ncpcardio0380

    Article  PubMed  CAS  Google Scholar 

  20. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56(4):1010–1013. doi:10.2337/db06-1656

    Article  PubMed  CAS  Google Scholar 

  21. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ (2007) Obesity and thrombosis. Eur J vasc endovasc surg : the official journal of the European Society for Vascular Surgery 33(2):223–233. doi:10.1016/j.ejvs.2006.10.006

    Article  CAS  Google Scholar 

  22. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR (1998) Biological action of leptin as an angiogenic factor. Science 281(5383):1683–1686

    Article  PubMed  CAS  Google Scholar 

  23. Soderberg S, Olsson T, Eliasson M, Johnson O, Ahren B (1999) Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 245(5):533–543

    Article  PubMed  CAS  Google Scholar 

  24. Faber DR, de Groot PG, Visseren FL (2009) Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes rev : an official journal of the International Association for the Study of Obesity 10(5):554–563. doi:10.1111/j.1467-789X.2009.00593.x

    Article  CAS  Google Scholar 

  25. Samad F, Pandey M, Loskutoff DJ (2001) Regulation of tissue factor gene expression in obesity. Blood 98(12):3353–3358

    Article  PubMed  CAS  Google Scholar 

  26. Lorenzet R, Napoleone E, Cutrone A, Donati MB (2012) Thrombosis and obesity: cellular bases. Thromb Res 129(3):285–289. doi:10.1016/j.thromres.2011.10.021

    Article  PubMed  CAS  Google Scholar 

  27. Anfossi G, Russo I, Trovati M (2009) Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis : NMCD 19(6):440–449. doi:10.1016/j.numecd.2009.01.006

    Article  PubMed  CAS  Google Scholar 

  28. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39(3):215–231

    Article  PubMed  CAS  Google Scholar 

  29. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87. doi:10.2165/11318100-000000000-00000

    Article  PubMed  CAS  Google Scholar 

  30. Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN (1996) Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci 91(6):679–683

    PubMed  CAS  Google Scholar 

  31. Abel ED, Litwin SE, Sweeney G (2008) Cardiac remodeling in obesity. Physiol Rev 88(2):389–419. doi:10.1152/physrev.00017.2007

    Article  PubMed  CAS  Google Scholar 

  32. Cheymol G (1988) Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 2(3):239–256

    Article  PubMed  CAS  Google Scholar 

  33. Benedek IH, Fiske WD 3rd, Griffen WO, Bell RM, Blouin RA, McNamara PJ (1983) Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 16(6):751–754

    Article  PubMed  CAS  Google Scholar 

  34. Wasan KM, Lopez-Berestein G (1993) The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res 24(4):395–401

    PubMed  CAS  Google Scholar 

  35. Blouin RA, Kolpek JH, Mann HJ (1987) Influence of obesity on drug disposition. Clinical pharmacy 6(9):706–714

    PubMed  CAS  Google Scholar 

  36. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA (2012) Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 51(5):277–304. doi:10.2165/11599410-000000000-00000

    Article  PubMed  CAS  Google Scholar 

  37. Buechler C, Weiss TS (2011) Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab 12(1):24–34

    Article  PubMed  CAS  Google Scholar 

  38. Pai MP (2010) Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 17(5):e53–e62. doi:10.1053/j.ackd.2010.05.010

    Article  PubMed  Google Scholar 

  39. Han PY, Duffull SB, Kirkpatrick CM, Green B (2007) Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 82(5):505–508. doi:10.1038/sj.clpt.6100381

    Article  PubMed  CAS  Google Scholar 

  40. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T, Leese PT (2002) Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 87(5):817–823

    PubMed  CAS  Google Scholar 

  41. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72(3):308–318. doi:10.1067/mcp.2002.127114

    Article  PubMed  CAS  Google Scholar 

  42. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK (2008) Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 18(2):162–166. doi:10.1007/s11695-007-9381-y

    Article  PubMed  Google Scholar 

  43. Martinez L, Burnett A, Borrego M, Streeter JC, Townsend K, Garcia D (2011) Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health-System pharm : AJHP : official journal of the American Society of Health-System Pharmacists 68(18):1716–1722. doi:10.2146/ajhp110010

    Article  CAS  Google Scholar 

  44. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O’Riordan W, Pineo GF, Investigators P (2007) The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369(9570):1347–1355. doi:10.1016/S0140-6736(07)60633-3

    Article  PubMed  CAS  Google Scholar 

  45. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343(7):457–462. doi:10.1056/NEJM200008173430702

    Article  PubMed  CAS  Google Scholar 

  46. Frederiksen SG, Hedenbro JL, Norgren L (2003) Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J surg 90(5):547–548. doi:10.1002/bjs.4068

    Article  PubMed  CAS  Google Scholar 

  47. Jimenez D, Diaz G, Iglesias A, Cesar J, Garcia-Avello A, Marti D, Escobar C, Vidal R, Sueiro A (2008) Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass. Arch Bronconeumol 44(12):660–663

    Article  PubMed  Google Scholar 

  48. Bara L, Leizorovicz A, Picolet H, Samama M (1992) Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin Post-surgery Logiparin Study Group. Thromb res 65(4–5):641–650

    Article  PubMed  CAS  Google Scholar 

  49. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, American College of Chest P (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e691S–e736S. doi:10.1378/chest.11-2300

    Article  PubMed  CAS  Google Scholar 

  50. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann pharmacother 43(6):1064–1083. doi:10.1345/aph.1L194

    Article  PubMed  CAS  Google Scholar 

  51. Scholten DJ, Hoedema RM, Scholten SE (2002) A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 12(1):19–24. doi:10.1381/096089202321144522

    Article  PubMed  Google Scholar 

  52. Simone EP, Madan AK, Tichansky DS, Kuhl DA, Lee MD (2008) Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 22(11):2392–2395. doi:10.1007/s00464-008-9997-6

    Article  PubMed  Google Scholar 

  53. Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC Jr, Guske PJ, Kane JM Jr, Gordon N, Sambol NC (2008) Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg obes Relat Dis : official journal of the American Society for Bariatric Surgery 4(5):625–631. doi:10.1016/j.soard.2007.11.010

    Article  Google Scholar 

  54. Singh K, Podolsky ER, Um S, Saba S, Saeed I, Aggarwal L, Zaya M, Castellanos A (2012) Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 22(1):47–51. doi:10.1007/s11695-011-0397-y

    Article  PubMed  Google Scholar 

  55. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC (2010) Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 125(3):220–223. doi:10.1016/j.thromres.2009.02.003

    Article  PubMed  CAS  Google Scholar 

  56. Hamad GG, Choban PS (2005) Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 15(10):1368–1374. doi:10.1381/096089205774859245

    Article  PubMed  Google Scholar 

  57. Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ (2005) Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 165(3):341–345. doi:10.1001/archinte.165.3.341

    Article  PubMed  CAS  Google Scholar 

  58. Simoneau MD, Vachon A, Picard F (2010) Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. Obes Surg 20(4):487–491. doi:10.1007/s11695-008-9738-x

    Article  PubMed  Google Scholar 

  59. Kalfarentzos F, Stavropoulou F, Yarmenitis S, Kehagias I, Karamesini M, Dimitrakopoulos A, Maniati A (2001) Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg 11(6):670–676. doi:10.1381/09608920160558588

    Article  PubMed  CAS  Google Scholar 

  60. Nagler M, Haslauer M, Wuillemin WA (2012) Fondaparinux—data on efficacy and safety in special situations. Thromb Res 129(4):407–417. doi:10.1016/j.thromres.2011.10.037

    Article  PubMed  CAS  Google Scholar 

  61. Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9

    Article  PubMed  CAS  Google Scholar 

  62. Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162(16):1833–1840

    Article  PubMed  CAS  Google Scholar 

  63. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105(3):444–453. doi:10.1160/TH10-09-0601

    Article  PubMed  CAS  Google Scholar 

  64. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kalebo P, Kwong LM, Misselwitz F, Turpie AG (2008) Population pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor–in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47(3):203–216

    Article  PubMed  CAS  Google Scholar 

  65. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594–604. doi:10.1056/NEJMoa0810773

    Article  PubMed  CAS  Google Scholar 

  66. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717):807–815. doi:10.1016/S0140-6736(09)62125-5

    Article  PubMed  CAS  Google Scholar 

  67. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487–2498. doi:10.1056/NEJMoa1006885

    Article  PubMed  CAS  Google Scholar 

  68. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest P (2012) Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e44S–e88S. doi:10.1378/chest.11-2292

    Article  PubMed  CAS  Google Scholar 

  69. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb haemost 101(1):77–85

    PubMed  CAS  Google Scholar 

  70. Yee JY, Duffull SB (2000) The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol 56(4):293–297

    Article  PubMed  CAS  Google Scholar 

  71. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest P (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S–e43S. doi:10.1378/chest.11-2291

    Article  PubMed  CAS  Google Scholar 

  72. Phung OJ, Kahn SR, Cook DJ, Murad MH (2011) Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 140(2):374–381. doi:10.1378/chest.10-3084

    Article  PubMed  CAS  Google Scholar 

  73. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 119:874–881

    Article  PubMed  CAS  Google Scholar 

  74. Kroon C, de Boer A, Kroon JM, Schoemaker HC, van den Meer FJ, Cohen AF (1991) Influence of skinfold thickness on heparin absorption. Lancet 337(8747):945–946

    Article  PubMed  CAS  Google Scholar 

  75. Quebbemann B, Akhondzadeh M, Dallal R (2005) Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg 15(9):1221–1224. doi:10.1381/096089205774512528

    Article  PubMed  Google Scholar 

  76. Fs M, Rosborough TK, Schwartz ML (2004) Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes Surg 14(5):601–605. doi:10.1381/096089204323093354

    Article  Google Scholar 

Download references

Conflict of interest

Authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Jacobi Medical Center, Albert Einstein College of Medicine of Yeshiva University, 1400 Pelham Pkwy, Bldg 1, Fl 3 North, Rm 21, Bronx, NY, 10461, USA

    K. Bakirhan & M. Strakhan

  2. 1563 Yates Avenue, 1F, Bronx, NY, 10461, USA

    K. Bakirhan

Authors
  1. K. Bakirhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Strakhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Bakirhan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bakirhan, K., Strakhan, M. Pharmacologic prevention of venous thromboembolism in obese patients. J Thromb Thrombolysis 36, 247–257 (2013). https://doi.org/10.1007/s11239-012-0844-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0844-1

Keywords

Search

Navigation